With the aim of differentiating lethal and non-lethal prostate cancer and ultimately improving the clinical outcome of subjects diagnosed with the disease, and based on the observed eNOS association with regulatory regions of annotated pri-miR (Table 1), we combined the ChIP-Seq approach with miR profiling in a subset of our PCa-derived cell populations [17] using an Exiqon platform. This evidence concerns the gene NOS3 and Familial prostate cancer.